Archive

Neovasc Announces Third Quarter 2018 Financial Results

NASDAQ, TSX: NVCN FDA has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment of refractory angina Reducer implanted in 100th patient in Germany Tiara™ (the "Tiara") featured in live case at the 32nd Annual European Association for Cardio-Thoracic Surgery (EACTS) Meeting...

Read More

Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

NASDAQ, TSX: NVCN VANCOUVER, Oct. 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

NASDAQ, TSX: NVCN VANCOUVER, Oct. 9, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More